BioBuzz

Biotech catalyst intelligence for disciplined event-driven trading.

BioBuzz tracks clinical trial catalysts, FDA and regulatory milestones, press releases, and financing events in a structured format built for serious biotech market participants.

Open free realtime Telegram alerts Join beta waitlist

Real-time alerts, for free

Receive real-time alerts straight to your device through our Telegram Channel

Beta waitlist

Join the waitlist for the searchable database and API access

Already have an account? Login

Real-time catalyst and regulatory alerting

Structured event timelines by symbol

Press release monitoring with direct source links

Clinical trial milestone tracking

Financing and runway watch

Market context for implied move awareness

Platform preview

Sample records below reflect the platform format. Full coverage, history depth, and filtering tools are available inside the product.

Symbol	Name	Implied Move	Expected Window	Context	Related PR
ALEC	PROGRESS-AD (Phase 2)	97.2%	Jan 01, 2026 - Jun 30, 2026	"The 76-week, global, randomized, double-blind, placebo-controlled PROGRESS-AD Phase 2 clinical trial of nivisnebart (AL101/GSK4527226) in early AD is ongoing, with enrollment completed in April 2025. An independent interim analysis is planned for the first half of 2026."	View Here
ALLO	ALPHA3 (Phase 2)	92.7%	Jan 01, 2026 - Jun 30, 2026	"Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL), ALPHA3 Positions Company at the Forefront of MRD-guided, Earlier-Line Oncology Treatment, Additional Sites in Australia and South Korea Expected to Open in early 2026, Scheduled Futility Analysis, Focused on MRD Conversion Between Study Arms, on Track for 1H 2026"	View Here
AVBP	FURVENT (Phase 3)	61.8%	Jan 01, 2026 - Jun 30, 2026	"Firmonertinib Pivotal EGFR exon 20 insertion data. Top-line firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study for first-line EGFR exon 20 insertion mutant NSCLC is projected to be in early 2026."	View Here
ADCT	LOTIS-5 (Phase 3)	309.1%	Jan 01, 2026 - Jun 30, 2026	"Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026"	View Here

ALEC

Name	PROGRESS-AD (Phase 2)
Implied Move	97.2%
Expected Window	Jan 01, 2026 - Jun 30, 2026
Context	"The 76-week, global, randomized, double-blind, placebo-controlled PROGRESS-AD Phase 2 clinical trial of nivisnebart (AL101/GSK4527226) in early AD is ongoing, with enrollment completed in April 2025. An independent interim analysis is planned for the first half of 2026."
Related PR	View Here

ALLO

Name	ALPHA3 (Phase 2)
Implied Move	92.7%
Expected Window	Jan 01, 2026 - Jun 30, 2026
Context	"Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL), ALPHA3 Positions Company at the Forefront of MRD-guided, Earlier-Line Oncology Treatment, Additional Sites in Australia and South Korea Expected to Open in early 2026, Scheduled Futility Analysis, Focused on MRD Conversion Between Study Arms, on Track for 1H 2026"

Loading preview catalysts...

Trust and coverage

Real-time alerts include source links and timestamps for direct verification.

Catalyst records are manually reviewed before publication and update propagation.

Scope and disclaimer

BioBuzz surfaces event intelligence and market context.

BioBuzz does not provide price targets, predictions, or trading recommendations.